-+ 0.00%
-+ 0.00%
-+ 0.00%

Roth Capital Reiterates Buy on Insmed, Lowers Price Target to $198

Benzinga·09/15/2026 16:40:33
Listen to the news
Roth Capital analyst Adam Walsh reiterates Insmed (NASDAQ:INSM) with a Buy and lowers the price target from $212 to $198.